BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Our new In Focus on organ-on-a-chip technology is live! CHECK IT OUT

Infographic: Key trends in antibody discovery

23 May 2023
Drug discovery and development Immunology Infographics Opinion Surveys

For our Spotlight on antibody discovery, we surveyed our audience to find out the latest trends, opinions and behaviors in the field. This infographic summarizes the results from the survey, including the most popular discovery techniques, the use of artificial intelligence and key challenges.

Illustration by Tobias Dumbraveanu.

Top content

  • GelGenie: magicking gel electrophoresis analysis into the 21st century
  • Pick of the posters: AACR 2025
  • First disease-specific markers for frontotemporal dementia

Related tags

antibody discovery
Previous article Next article

Related articles

17 MAR 2023 DRUG DISCOVERY AND DEVELOPMENT

Advanced flow cytometry applications for antibody, small molecule and phenotypic screening

17 MAR 2023 DRUG DISCOVERY AND DEVELOPMENT

Utilizing advanced high-throughput flow cytometry to quantify direct and competitive live cell antibody binding

17 MAR 2023 DRUG DISCOVERY AND DEVELOPMENT

High-throughput, multi-parametric analysis accelerates antibody discovery workflows

23 MAY 2024 IMMUNOLOGY

Evolving an antibody: innovation in therapeutic antibody design

5 APR 2023 DRUG DISCOVERY AND DEVELOPMENT

When less is more: reducing immunomodulatory antibody affinity boosts anticancer activity

25 JUN 2024 DRUG DISCOVERY AND DEVELOPMENT

eBook | VHH antibody engineering: a new tool for the therapeutic development pipeline

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques